Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 (2026-02-04)
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.